{
  "abstract": "Pancreatic cancer remains among the deadliest malignancies, with a 5-year survival of ~13%. Chimeric antigen receptor (CAR) T -cell therapy offers hope, but conventional αβ T cells can trigger severe toxicities, including graft-versus-host disease (GvHD) when used for allogeneic therapy. By contrast, γδ T cells recognize tumors without MHCmajor histocompatibility complex restriction and are unlikely to cause GvHD, making them attractive candidates for “off-the-shelf” immunotherapy. Li et al engineered the Vδ1 subset of γδ T cells with a CAR targeting prostate stem cell antigen (PSCA) and compared these cells to CAR-engineered Vδ2 γδ and conventional αβ T cells in preclinical pancreatic cancer models. All three groups showed comparable tumor killing efficacy, but the CAR Vδ1 T cells induced none of the GvHD or systemic toxicity seen with CAR αβ T cells. They also displayed lower exhaustion than CAR Vδ2 cells, suggesting potential for greater persistence. Vδ1 CAR T cells could be expanded robustly ex vivo and remained highly potent even after cryopreservation, a key “off-the-shelf” requirement. These findings position CAR Vδ1 T cells as a safer alternative to traditional CAR T cells. Future rigorous clinical evaluation will be needed to confirm superior safety and efficacy of this promising approach in patients.",
  "authors": [
    {
      "affiliations": [
        "Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA",
        "Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA",
        "Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA",
        "Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, Pennsylvania, USA"
      ],
      "name": "Joseph A Fraietta"
    },
    {
      "affiliations": [
        "Division of Surgical Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA",
        "UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA",
        "Center for Systems Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"
      ],
      "name": "Jason J Lohmueller"
    }
  ],
  "title": "PSCA CAR Vδ1 T cells: a safer off-the-shelf CAR T therapy for pancreatic cancer?",
  "uid": "56767970-385e-5fa8-97c5-b2f8ff600e68"
}